National Graphite Corp
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
Financial Services
Sector
Shell Companies
Industry
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications.
Similar securities
Based on sector and market capitalization
Report issue